Join us as we discuss BlueRock Therapeutic's new cell therapy DA01 currently in phase I clinical trials. Dr. Fasano and Dr. Enayetallah break down how this therapy has the potential to revolutionize the Parkinson's treatment landscape by providing tonic dopamine release and addressing underlying neuron degeneration.  
Learn more about the clinical trial <a href="https://clinicaltrials.gov/ct2/show/NCT04802733">here</a>. 
Access the transcript <a href="https://mcgillstudentsforp3.wixsite.com/mcgillparkinsonsclub/programs">here</a>.

Join us as we discuss BlueRock Therapeutic's new cell therapy DA01 currently in phase I clinical trials. Dr. Fasano and Dr. Enayetallah break down how this therapy has the potential to revolutionize the Parkinson's treatment landscape by providing tonic dopamine release and addressing underlying neuron degeneration. Learn more about the clinical trial here. Access the transcript here.

Join us as we discuss BlueRock Therapeutic's new cell therapy DA01 currently in phase I clinical trials. Dr. Fasano and Dr. Enayetallah break down how this therapy has the potential to revolutionize the Parkinson's treatment landscape by providing tonic dopamine release and addressing underlying neuron degeneration. &nbsp;
Learn more about the clinical trial <a href="https://clinicaltrials.gov/ct2/show/NCT04802733" rel="noopener noreferrer">here</a>.&nbsp;
Access the transcript <a href="https://mcgillstudentsforp3.wixsite.com/mcgillparkinsonsclub/programs" rel="noopener noreferrer">here</a>.&nbsp;

Emerging cell therapy DA01 with BlueRock Therapeutics

Run by students from McGill University's Students for Parkinson's Awareness club, we interview leading researcher in the field of Neurodegeneration to bring our audience awareness of recent, innovative research findings on the origins, progression, and treatment of Parkinson's Disease

Share Emerging cell therapy DA01 with BlueRock Therapeutics

Sign up to save your podcasts

Emerging cell therapy DA01 with BlueRock Therapeutics

Emerging cell therapy DA01 with BlueRock Therapeutics